Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Research & Development (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Research & Development over the past 9 years, most recently at $7.0 million for Q4 2023.

  • For Q4 2023, Research & Development rose 11.81% year-over-year to $7.0 million; the TTM value through Dec 2023 reached $31.2 million, up 93.15%, while the annual FY2024 figure was $32.2 million, 3.38% up from the prior year.
  • Research & Development for Q4 2023 was $7.0 million at Corbus Pharmaceuticals Holdings, up from $6.6 million in the prior quarter.
  • Over five years, Research & Development peaked at $30.7 million in Q2 2020 and troughed at $380000.0 in Q4 2021.
  • A 5-year average of $13.3 million and a median of $11.0 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 97.64% in 2021 and later skyrocketed 1542.83% in 2022.
  • Year by year, Research & Development stood at $23.5 million in 2019, then plummeted by 31.41% to $16.1 million in 2020, then plummeted by 97.64% to $380000.0 in 2021, then skyrocketed by 1542.83% to $6.2 million in 2022, then grew by 11.81% to $7.0 million in 2023.
  • Business Quant data shows Research & Development for CRBP at $7.0 million in Q4 2023, $6.6 million in Q3 2023, and $4.2 million in Q2 2023.